Wall Street analyst estimates for Skye Bioscience, Inc. (SKYE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-1.14 | ||
| 2026-08-14 | $-2.16 | $-2.04 | -5.9% |
| 2026-05-11 | $-0.32 | $-0.29 | -10.3% |
| 2026-03-19 | $-2.88 | $-2.32 | -24.1% |
| 2025-11-10 | $-2.56 | $-2.64 | +3.0% |
| 2025-08-08 | $-0.44 | $-2.72 | +83.8% |
| 2025-05-08 | $-0.28 | $-2.48 | +88.7% |
| 2025-03-20 | $-0.24 | $-2.24 | +89.3% |
Valuation Ratios
| Price / Book | 1.49 |
| EV / EBITDA | -0.44 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $14916 | $8038 | $1544 | $1462 | $1872 | 0 | 0 | 0 | 0 | $723352 |
| Gross Profit | -$14916 | -$8038 | -$1544 | -$1462 | -$1872 | 0 | 0 | 0 | 0 | -$723352 |
| Research & Development | $939040 | $311302 | $329966 | $2.2M | $1.9M | $2.9M | $6.0M | $5.8M | $18.7M | $42.4M |
| Selling, General & Admin | $3.5M | $3.5M | $4.4M | $4.4M | $4.3M | $4.9M | $6.1M | $7.9M | $17.7M | $15.8M |
| Operating Expenses | $4.5M | $3.9M | $4.7M | $6.6M | $6.3M | $7.8M | $18.3M | $34.7M | $30.2M | $57.4M |
| Operating Income | -$4.5M | -$3.9M | -$4.7M | -$6.6M | -$6.3M | -$7.8M | -$18.3M | -$34.7M | -$30.2M | -$58.2M |
| EBITDA | 0 | -$3.1M | -$4.7M | $2.0M | -$5.9M | -$7.7M | -$18.7M | -$36.6M | -$25.3M | -$55.2M |
| Interest Expense | 0 | $667 | $94763 | $1.0M | $706385 | $767511 | $663774 | $906270 | $967602 | 0 |
| Pre-tax Income | -$3.2M | -$3.1M | -$19.2M | $1.1M | -$6.6M | -$8.5M | -$19.5M | -$37.6M | -$26.6M | -$55.9M |
| Income Tax | $1600 | $1600 | $1642 | $1600 | $1600 | $2100 | $6741 | $3600 | $10071 | $5400 |
| Net Income | -$3.2M | -$3.1M | -$19.2M | $1.1M | -$6.6M | -$8.5M | -$19.5M | -$37.6M | -$26.6M | -$55.9M |
| EPS | $-335.44 | $-204.96 | $-292.08 | $15.84 | $-56.88 | $-40.00 | $-70.16 | $-42.96 | $-5.84 | $-11.28 |
| EPS (Diluted) | $-319.20 | $-204.96 | $-292.08 | $15.84 | $-59.68 | $-40.00 | $-70.16 | $-42.96 | $-5.84 | $-11.28 |
| Shares Outstanding (Diluted) | $9957 | $15096 | $65723 | $66501 | $115710 | $203300 | $277635 | $875750 | $4.6M | $5.0M |
Price
| Price | $1.70 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALGS · BRNS · CVM · INMB · KZR · LVTX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of SKYE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks